Neurogene(NASDAQ) NGNE

Neurogene Inc. makes genetic medicines for severe brain disorders. These treatments fix the underlying causes of rare neurological diseases. The products help patients regain or improve essential physical functions.

What Neurogene Makes

• NGN-401: An investigational gene therapy for Rett syndrome, a severe neurodevelopmental disease in females; it delivers a full-length gene to brain cells through a specialized injection.
• EXACT Platform: A technology that uses genetic circuits to control how much medicine the brain receives; it aims to provide therapeutic levels without causing harm from over-exposure.
• Manufacturing Site: An internal factory in Houston, Texas, used to create clinical-grade genetic materials for patient trials and future commercial use.
• NGN-101: A therapy targeting a rare form of Batten disease, which causes loss of vision and motor skills; development is currently paused while the company evaluates options.

Building the Research Pipeline

• Extended a research agreement with the University of Edinburgh in November 2023 to develop new genetic medicine candidates.
• Received Breakthrough Therapy status from the FDA in February 2026 for its lead program to speed up clinical development.
• Signed a licensing deal with Stanford University in August 2024 for biological materials used in the manufacturing process.
• Raised $134.8 million in net proceeds through a public stock offering in July 2026 to fund ongoing clinical trials.

Controlling the Genetic Dose

Neurogene uses its EXACT technology to solve the common problem of toxic over-expression in gene therapy. The company maintains its own manufacturing plant to control production quality and speed up its clinical development timelines.

The Financial Scorecard

• Market capitalization was $709.3 million in the second quarter of 2026, up 125.3% year over year.
• Net loss was $65.4 million for the six months ended June 30, 2026.
• Research and development expenses totaled $50.6 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and short-term investments reached $225.4 million as of June 30, 2026.
• Accumulated deficit since the company began operations was $418.1 million as of June 30, 2026.

Bottom Line

Neurogene has evolved from an early research firm into a clinical-stage developer with its own internal manufacturing capabilities. The company uses precision genetic engineering to address complex neurological conditions that traditional therapies cannot treat.